| Literature DB >> 33504245 |
Angeliki Bogosian1, Catherine S Hurt1, John V Hindle2, Lance M McCracken3, Debora A Vasconcelos E Sa1, Sandra Axell1, Katy Tapper4, Jemima Stevens4, P Shashi Hirani1, Marya Salhab1, Wenrong Ye5, Patricia Cubi-Molla6.
Abstract
Mindfulness-based group therapy is a rapidly growing psychological approach that can potentially help people adjust to chronic illness and manage unpleasant symptoms. Emerging evidence suggests that mindfulness-based interventions may benefit people with Parkinson's. The objective of the paper is to examine the appropriateness, feasibility, and potential cost-effectiveness of an online mindfulness intervention, designed to reduce anxiety and depression for people with Parkinson's. We conducted a feasibility randomized control trial and qualitative interviews. Anxiety, depression, pain, insomnia, fatigue, impact on daily activities and health-related quality of life were measured at baseline, 4, 8, and 20 weeks. Semi-structured interviews were conducted at the end of the intervention. Participants were randomized to the Skype delivered mindfulness group (n = 30) or wait-list (n = 30). Participants in the mindfulness group were also given a mindfulness manual and a CD with mindfulness meditations. The intervention did not show any significant effects in the primary or secondary outcome measures. However, there was a significant increase in the quality of life measure. The incremental cost-effectiveness ratio was estimated to be £27,107 per Quality-Adjusted Life Year gained. Also, the qualitative study showed that mindfulness is a suitable and acceptable intervention. It appears feasible to run a trial delivering mindfulness through Skype, and people with Parkinson's found the sessions acceptable and helpful.Entities:
Keywords: EQ-5D; Parkinson’s; anxiety; depression; mindfulness
Mesh:
Year: 2021 PMID: 33504245 PMCID: PMC8678660 DOI: 10.1177/0891988720988901
Source DB: PubMed Journal: J Geriatr Psychiatry Neurol ISSN: 0891-9887 Impact factor: 2.680
Figure 1.CONSORT flow diagram.
Topic Guide for Participants’ Experiences With the Mindfulness Course.
| Questions | Prompts |
|---|---|
| 1. Can you start by telling me what you were expecting from the mindfulness sessions? | – What did you think the programme would be like? |
| 2. How did you find the programme overall? | – Tell me how you found your first session |
| 3. Can you tell me what you liked about the programme? | – What was helpful? Why? How? |
| 4. Can you tell me what you disliked about the programme? | – What was unhelpful? Why? How? |
| 5. Tell me about anything that you feel has changed from having done the programme? | – Can you tell me what changed? (anything different in your day-to-day life, the way you are dealing with Parkinson’s?) |
| 6. Do you have anything else you would like to tell me about your experiences of this programme that haven’t already covered? | – What would you feed back to the people who put together the programme? |
| 7. What do you think of the questionnaires used and the overall set up of the study? | – How did you find participating in a course over Skype? |
Demographics and Baseline Clinical Characteristics of Participants.
| Variable | Mindfulness (n = 30) | Wait-list (n = 30) | Statistical test |
|---|---|---|---|
| Gender, female (n, %) | 13 (43.3) | 17 (56.7) | χ2 = 1.067, p = .302 |
| Age, in years (M, SD) | 59.50 (11.12) | 62.23 (8.96) | t(58) = 1.048, p = .299 |
| Years since diagnosis (M, SD) | 5.22 (3.55) | 6.43 (3.85) | t(58) = 1.273, p = .208 |
| Disease severity (PADLS) (M, SD) | 2.10 (0.61) | 2.13 (0.68) | t = .200, p = .0842 |
| Anxiety (HADS) (M, SD) | 8.70 (4.23) | 7.73 (3.59) | t(58) = −.960, p = .341 |
| Depression (HADS) (M, SD) | 7.23 (3.46) | 5.73 (3.00) | t(58) = −1.778, p = .08 |
Estimated Post-Therapy Group Differences (Treatment Effects) for Primary, Secondary Outcomes.
| Mindfulness | WLC | ||||||
|---|---|---|---|---|---|---|---|
| Mean (SD) | CI (LB-UB) | Mean (SD) | CI (LB-UB) | Mean* diff | Effect size* | ||
| Anxiety | baseline | 8.70 (4.24) | 7.26-10.13 | 7.73 (3.59) | 6.30-9.17 | −0.97 | 0.25 |
| mid-intervention | 7.27 (4.88) | 5.67-8.86 | 6.40 (3.80) | 4.80-8.00 | −0.87 | 0.20 | |
| post-intervention | 7.53 (4.22) | 6.07-9.00 | 6.20 (3.75) | 4.74-7.66 | −1.33 | 0.33 | |
| follow-up | 6.97 (4.44) | 5.44-8.49 | 6.17 (3.87) | 4.64-7.69 | −0.80 | 0.19 | |
| Depression | baseline | 7.23 (3.46) | 6.05-8.42 | 5.73 (3.00) | 4.55-6.92 | −1.50 | 0.46 |
| mid-intervention | 6.27 (3.84) | 5.02-7.51 | 5.13 (2.89) | 3.89-6.37 | −1.14 | 0.34 | |
| post-intervention | 5.53 (3.74) | 4.26-6.80 | 5.33 (3.20) | 4.06-6.60 | −0.20 | 0.06 | |
| follow-up | 6.03 (4.13) | 4.71-7.36 | 5.33 (3.06) | 4.01-6.66 | −0.70 | 0.19 | |
| Pain | Baseline | 3.57 (2.01) | 2.77-4.37 | 3.41 (2.38) | 2.60-4.21 | −0.16 | 0.07 |
| mid-intervention | 3.34 (2.10) | 2.53-4.16 | 3.56 (2.35) | 2.74-4.37 | 0.22 | 0.10 | |
| post-intervention | 3.21 (2.22) | 2.39-4.04 | 3.32 (2.31) | 2.49-4.15 | 0.11 | 0.05 | |
| follow-up | 3.75 (2.17) | 2.99-4.60 | 3.60 (2.47) | 2.75-4.45 | −0.15 | 0.06 | |
| Fatigue | Baseline | 4.08 (1.30) | 3.54-4.62 | 4.01 (1.62) | 3.47-4.54 | −0.07 | 0.05 |
| mid-intervention | 4.18 (1.30) | 3.63-4.73 | 3.69 (1.69) | 3.14-4.24 | −0.49 | 0.33 | |
| post-intervention | 4.20 (1.16) | 3.68-4.71 | 3.96 (1.64) | 3.44-4.48 | −0.24 | 0.17 | |
| follow-up | 4.39 (1.30) | 3.83-4.94 | 4.04 (1.72) | 3.48-4.60 | −0.35 | 0.23 | |
| Insomnia | Baseline | 11.17 (5.38) | 9.02-13.31 | 9.27 (6.31) | 7.12-11.41 | −1.90 | 0.32 |
| mid-intervention | 16.10 (6.68) | 13.65-18.55 | 15.20 (6.72) | 12.75-17.65 | −0.90 | 0.13 | |
| post-intervention | 16.00 (6.01) | 13.73-18.27 | 15.40 (6.42) | 13.13-17.67 | −0.60 | 0.10 | |
| follow-up | 16.57 (6.01) | 14.20-18.93 | 16.17 (6.89) | 13.80-18.53 | −0.13 | 0.06 | |
| Impact of Parkinson’s | Baseline | 2.10 (0.61) | 1.86-2.34 | 2.13 (0.68) | 1.89-2.37 | 0.03 | 0.04 |
| Mid-intervention | 2.07 (0.69) | 1.82-2.32 | 2.03 (0.67) | 1.79-2.30 | −0.04 | 0.06 | |
| post-intervention | 2.00 (0.74) | 1.73-2.27 | 2.10 (0.71) | 1.83-2.37 | 0.10 | 0.14 | |
| follow-up | 2.03 (0.77) | 1.73-2,34 | 2.23 (0.90) | 1.93-2.54 | 0.20 | 0.24 | |
* Mean difference and effect sizes reflect between groups differences.
ANOVA Results for Primary and Secondary Outcomes.
|
|
|
|
| ||
|---|---|---|---|---|---|
| Anxiety | |||||
| Time | 3, 174 | 12.61 | <.001 | .1790 | |
| Group | 1, 58 | .98 | .325 | .017 | |
| Group x Time | 3,174 | .32 | .809 | .006 | |
| Depression | |||||
| Time | 2.611, 151.431 | 5.49 | .002 | .086 | |
| Group | 1, 58 | 1.16 | .287 | .020 | |
| Group x Time | 2.611, 151.431 | 2.08 | .114 | .035 | |
| Pain | |||||
| Time | 2.474, 143.493 | 2.23 | .099 | .037 | |
| Group | 1, 58 | .00 | .996 | .000 | |
| Group x Time | 2.474, 143.493 | .69 | .533 | .012 | |
| Fatigue | |||||
| Time | 3, 174 | 1.78 | .154 | .030 | |
| Group | 1, 58 | .65 | .424 | .011 | |
| Group x Time | 3, 174 | 1.00 | .392 | .017 | |
| Insomnia | |||||
| Time | 3, 174 | 66.11 | .001 | .553 | |
| Group | 1, 58 | .39 | .533 | .007 | |
| Group x Time | 3, 174 | .89 | .446 | .015 | |
| Impact of Parkinson’s | |||||
| Time | 3, 174 | .90 | .446 | .015 | |
| Group | 1, 58 | .20 | .659 | .003 | |
| Group x Time | 3, 174 | 1.15 | .330 | .019 | |
Figure 2.Change in health-related quality of life (HRQoL) in the mindfulness (MBI) and wait-list control (WLC) group.